1. Home
  2. DSY vs XFOR Comparison

DSY vs XFOR Comparison

Compare DSY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSY
  • XFOR
  • Stock Information
  • Founded
  • DSY 2020
  • XFOR 2014
  • Country
  • DSY China
  • XFOR United States
  • Employees
  • DSY N/A
  • XFOR N/A
  • Industry
  • DSY
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DSY
  • XFOR Health Care
  • Exchange
  • DSY Nasdaq
  • XFOR Nasdaq
  • Market Cap
  • DSY 130.7M
  • XFOR 118.4M
  • IPO Year
  • DSY N/A
  • XFOR N/A
  • Fundamental
  • Price
  • DSY $3.25
  • XFOR $0.61
  • Analyst Decision
  • DSY
  • XFOR Strong Buy
  • Analyst Count
  • DSY 0
  • XFOR 3
  • Target Price
  • DSY N/A
  • XFOR $3.50
  • AVG Volume (30 Days)
  • DSY 43.9K
  • XFOR 3.4M
  • Earning Date
  • DSY 02-10-2025
  • XFOR 11-13-2024
  • Dividend Yield
  • DSY N/A
  • XFOR N/A
  • EPS Growth
  • DSY 120.37
  • XFOR N/A
  • EPS
  • DSY 0.01
  • XFOR N/A
  • Revenue
  • DSY $7,323,356.00
  • XFOR $1,123,000.00
  • Revenue This Year
  • DSY N/A
  • XFOR N/A
  • Revenue Next Year
  • DSY N/A
  • XFOR $476.54
  • P/E Ratio
  • DSY $263.78
  • XFOR N/A
  • Revenue Growth
  • DSY 16.37
  • XFOR N/A
  • 52 Week Low
  • DSY $0.75
  • XFOR $0.26
  • 52 Week High
  • DSY $13.47
  • XFOR $1.60
  • Technical
  • Relative Strength Index (RSI)
  • DSY 49.97
  • XFOR 54.99
  • Support Level
  • DSY $2.82
  • XFOR $0.58
  • Resistance Level
  • DSY $3.77
  • XFOR $0.83
  • Average True Range (ATR)
  • DSY 0.49
  • XFOR 0.13
  • MACD
  • DSY 0.03
  • XFOR 0.02
  • Stochastic Oscillator
  • DSY 42.48
  • XFOR 49.48

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: